Biosimilar Diplomacy By Other Means: GPhA CEO Calls Out Amgen Guest
This article was originally published in The Pink Sheet Daily
Executive Summary
During speech to the group’s annual meeting, GPhA President Ralph Neas says he is disappointed that Amgen, which is among the firms attending the gathering, is pushing biosimilar substitution restrictions in state legislatures.
You may also be interested in...
If You Can't Beat 'Em … Hire 'Em? PhRMA Exec Is New GPhA CEO
Chip Davis still believes in innovation, but now must balance that with affordability in new role leading the generic association.
GPhA’s Goals For 2013: Smooth GDUFA Implementation, Workable Biosimilar Pathway
The generic drug trade association’s cross-cutting priorities are the result of an extensive strategic planning process, CEO Ralph Neas says; the group is planning outreach to Congress and the executive branch to highlight the role generic drugs can play in helping to address the nation’s fiscal problems.
Draft Guidances For 2013 Will Grapple With Biosimilars, Track and Trace, Compounding
FDA’s Center for Drug Evaluation and Research plans to publish more than 50 new and revised draft guidances this calendar year.